Actelion Stock Xetra

Stocks

31/07/17	Actelion : France's Sanofi raises earnings forecast, pleased with eczema drug uptake	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
19/07/17	Johnson & Johnson : J&J sees sales growth in near-term; raises 2017 profit forecast	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
10/06/17	Actelion : Johnson & Johnson expects to complete Actelion purchase on June 16	RE
09/06/17	Actelion : Johnson & Johnson expects to complete of Actelion offer on June 16	RE
22/05/17	Akzo Nobel : Cross-border M&A between U.S. and European firms at 10 year high	RE
18/05/17	Actelion : Johnson & Johnson offers EU concessions over Actelion deal	RE
20/04/17	Actelion : Johnson & Johnson target Actelion could exit Swiss benchmark SMI index this month	RE
18/04/17	Actelion : Johnson & Johnson first quarter revenue misses estimates; new forecast includes Actelion	RE
05/04/17	Actelion : shareholders back R&D spinoff, keep J&J deal on track	RE
31/03/17	Actelion : J&J declares Actelion tender offer a success, sees closing in second quarter	RE
23/02/17	Genmab A/S : and J&J's cancer drug set for blockbuster sales this year	RE

06/04/20	Actelion : Pharmaceuticals US, Inc, - Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents	AQ
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017	GL
30/06/17	Actelion : Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung	GL
16/06/17	Actelion : Johnson & Johnson Completes Acquisition of Actelion	GL
16/06/17	Actelion : Publication of Idorsia's prospectus relating to the listing of Idorsia Ltd on SIX Swiss Exchange	PU

29/01/18	Après Bioverativ, Sanofi s'empare de la biotech belge Ablynx pour 3,9 mrd EUR
29/01/18	Après Bioverativ, Sanofi rachète la biotech belge Ablynx pour 3,9 mrd EUR
22/01/18	Avec Bioverativ, Sanofi devient un leader mondial dans l'hémophilie
31/10/17	Actelion : Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017
30/10/17	Actelion: la décotation est agendée au 7 novembre

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACTELION	-.--%	-.--%	-	-	0
ARGENX SE	+0.20%	+0.47%	+74.97%	+134.12%	57.73B
WUXI APPTEC CO., LTD.	-0.93%	-2.54%	+73.64%	+93.71%	54.69B
BIONTECH SE	-3.71%	-0.35%	-14.61%	-11.19%	23.75B
INSMED INCORPORATED	-0.05%	+6.49%	+14.05%	+451.36%	24.18B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	+6.30%	+46.83%	-2.70%	19.82B
GENMAB A/S	+3.19%	+4.82%	+43.85%	-26.82%	17.14B
PHARMAESSENTIA CORPORATION	+3.58%	+13.78%	+196.41%	+348.55%	16.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.81%	+17.84%	+45.86%	-	15.57B
EXELIXIS, INC.	-0.57%	+2.30%	+20.33%	+187.27%	13.96B
Average	-0.28%	+5.80%	+55.70%	+146.79%	27.06B
Weighted average by Cap.	-0.41%	+4.15%	+58.77%	+137.95%

Employees

Sector